SEC Form 4 · accession 0000950138-17-000174
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Trudeau
Officer — President and CEO · Director
Period of report
Feb 14, 2017
Accepted (ET)
Feb 15, 2017 · 8:49 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Feb 14, 2017 | P | 1,000 | $50.4664 | A | 262,680 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $50.45 to $50.49, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.
- F2Includes 128 shares acquired on December 31, 2016 under the Mallinckrodt employee stock purchase plan.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.